A pharmaceutical composition of peridinin and doxorubicin and application thereof
By combining doxorubicin with doxorubicin, the problem of multidrug resistance in the treatment of breast cancer with doxorubicin was solved, achieving significant inhibition of the proliferation of doxorubicin-resistant cells and excellent tumor-suppressing effects, while maintaining good safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- EAST CHINA UNIV OF SCI & TECH
- Filing Date
- 2026-04-28
- Publication Date
- 2026-07-17
AI Technical Summary
Doxorubicin is prone to multidrug resistance when treating breast cancer, especially for some subtypes (such as ER+), and there is a lack of effective treatment options to reverse resistance.
A pharmaceutical composition is prepared by combining daunoflavin and doxorubicin in a preferred molar ratio of 6.5:1 to 27.2:1, including pharmaceutically acceptable excipients, and in the form of an injection, tablet, capsule or topical dosage form for the treatment of breast cancer.
In vitro experiments showed that the combination of doxydin and doxorubicin significantly inhibited the proliferation of doxorubicin-resistant cells compared to doxorubicin alone. In vivo experiments demonstrated excellent tumor-suppressing effects with no significant systemic toxicity and good safety profile.
Smart Images
Figure CN122398831A_ABST